Miglustat Accord (Miglustat)

Miglustat Accord acts on the glycosphingolipid synthesis pathway, providing substrate reduction for lysosomal storage disorders.

• Type 1 Gaucher disease: reduces glycosphingolipid buildup, helping to control organ enlargement, bone disease and hematologic abnormalities.
• Niemann‑Pick disease type C: decreases substrate accumulation, supporting neurological and systemic symptom management.

• Miglustat inhibits the enzyme glucosylceramide synthase, the first step in the biosynthesis of glycosphingolipids. By blocking this enzyme, the drug lowers the production of glucosylceramide and downstream complex glycosphingolipids, thereby reducing the pathological substrate that accumulates in lysosomal storage disorders such as Gaucher disease type 1 and Niemann‑Pick disease type C.

Miglustat may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: sensation of unease in the stomach, may be transient.
• Abdominal pain: cramping or discomfort in the abdomen.
• Weight loss: gradual decrease in body weight, usually modest.
• Flatulence: increased intestinal gas.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Severe pancreatitis: acute inflammation of the pancreas requiring urgent care.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Elevated liver enzymes: possible hepatic injury, monitored by blood tests.
• Depression or mood changes: new or worsening psychiatric symptoms.
• Seizures: rare neurologic events.
• Severe gastrointestinal bleeding: uncommon but potentially life‑threatening.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Dose adjustment: assess renal function and consider dose modification in renal impairment.
• Gastrointestinal tolerance: advise patients to take the medication with meals and maintain adequate hydration.
• Hepatic monitoring: perform baseline and periodic liver function tests.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Pregnancy and lactation: prescribe only when the expected benefit justifies potential risk to the fetus or infant.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Miglustat can affect the pharmacokinetics of several co‑administered medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Oral contraceptives: miglustat may diminish hormonal effectiveness, increasing the risk of unintended pregnancy.
• Other substrate‑reduction agents: combined use can amplify toxicity and should be avoided.

Moderate Interactions (Monitor Closely)

• Antacids or alkaline substances: may reduce miglustat absorption; separate dosing by at least 2 hours.
• Warfarin: monitor INR more frequently as miglustat may alter anticoagulant response.
• Drugs causing gastrointestinal irritation: concurrent use may exacerbate GI side effects, requiring dose adjustment or symptom management.